Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease

Chest

Volumn 130, Issue 4, 2006, Pages 976-981

  Fischer, Aryeh ^a   Meehan, Richard T ^a   Feghali Bostwick, Carol A ^c   West, Sterling G ^b   Brown, Kevin K ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti Th To antibodies; Interstitial lung disease; Systemic sclerosis sine scleroderma

Indexed keywords

ANTINUCLEAR ANTIBODY; SCL 70 ANTIBODY;

ADULT; AGED; CAPILLAROSCOPY; CAUCASIAN; CLINICAL ARTICLE; CLINICAL FEATURE; ECHOCARDIOGRAPHY; ESOPHAGOGRAPHY; ESOPHAGUS MOTILITY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IDIOPATHIC DISEASE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; MALE; PATIENT REFERRAL; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; SYSTEMIC SCLEROSIS SINE SCLERODERMA; TELANGIECTASIA;

EID: 33750087827     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.4.976     Document Type: Article

References (36)

1. Steen VD. Epidemiology of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, et al, eds. Rheumatology. Madrid, Spain: Elsevier Limited, 2003; 1455-1462
2. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003; 29:371-390
3. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28:2454-2459
4. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437-2444
5. Altman RD, Medsger TA, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34:403-413
6. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology 2002; 41:676-679
7. King TE. Approach to the patient with interstitial lung disease. In: Crapo JD, Glassroth J, Karlinsky JB, et al, eds. Baum's textbook of pulmonary diseases. Philadelphia, PA: Lippincott, Williams & Wilkins, 2004; 455-468
8. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25:549-559
9. Reveille JD, Solomon DH, and the ACR Ad HOC Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res 2003; 49:399-412
10. Reimer G, Steen VD, Penning CA, et al. Correlates between autoantibodies to nuclear antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988; 31:525-532
11. Reichlin M, Maddison PJ, Targoff IN, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984; 4:40-44
12. Harvey G, Black C, Maddison P, et al. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997; 24:477-484
13. Chung L, Utz PJ. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheum Rep 2004; 6:156-163
14. Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To- and anticentromere-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48:203-209
15. Feghali-Bostwick C, Medsger TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high for concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48:1956-1963
16. Kuwana M, Feghali CA, Medsger TA, et al. Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis Rheum 2001; 44:1654-1659
17. Falkner D, Wilson J, Fertig N, et al. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000; 27:1196-1202
18. Tashkin DP, Elashoff R, Clements PJ, et al, for the Scleroderma Lung Study Research Group. Cyclophosphamide vs placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666
19. Homma Y, Ohtsuka Y, Tanimura K, et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration 1995; 62:248-251
20. Lomeo RM, Cornella RJ, Schabel SI, et al. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial flbrosis. Am J Med 1989; 87:525-527
21. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am 1996; 22:841-860
22. Smith JW, Clements PJ, Levisman J, et al. Echocardiographic features of progressive systemic sclerosis (PSS): correlation with hemodynamic and postmortem studies. Am J Med 1979; 66:28-33
23. Gottdiener JS, Mousopoulos HM, Decker JL. Echocardiographic identification of cardiac abnormality in scleroderma and related disorders. Am J Med 1979; 66:391-398
24. Gaffney FA, Anderson RJ, Nixon JV, et al. Cardiovascular function in patients with progressive systemic sclerosis (scleroderma). Clin Cardiol 1982; 5:569-576
25. Steen V, Medgser TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516-522
26. Fischer A, Meehan RT, Ulrich SK, et al. Asymptomatic pericardial disease in scleroderma-associated progressive interstitial lung disease and its relationship to pulmonary hypertension [abstract]. Arthritis Rheum 2005; 52(9S):S170
27. Bacque-Juston MC, Wells AU, Hansell DM. Pericardial thickening or effusion in patients with pulmonary artery hypertension: a CT study. AJR Am J Roentgenol 1999; 172:361-364
28. Hinderliter AL, Willis PW, Long W, et al, for the PPH Study Group. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. Am J Cardiol 1999; 84:481-484
29. Raymond RJ, Hinderliter AL, Willis PW, et al, for the PPH Study Group. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39:1214-1219
30. Hardin JA, Rahn DR, Shen C, et al. Antibodies from patients with connective tissue diseases bind specific subsets of cellular RNA-protein particles. J Clin Invest 1982; 70:141-147
31. van Eenennaam H, Vogelzangs JHP, Lugtenberg D, et al. Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002; 46:3266-3272
32. Reddy R, Tan EM, Henning D, et al. Detection of a nucleolar 7-2 ribonucleoprotein and cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983; 258:1383-1386
33. Gold HA, Craft J, Hardin JA, et al. Antibodies in human serum that precipitate ribonuclease P. Proc Natl Acad Sci USA 1988; 85:5483-5487
34. Gold HA, Topper JN, Clayton DA, et al. The RNA processing enzyme RNase MRP is identical to the Th RNP and related to RNase P. Science 1989; 245:1377-1380
35. Okano Y, Medsger TA. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990; 33:1822-1828
36. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444-451